MORE►
gene editing
The Colossal Foundation is partnering with the University of Tasmania on an initiative to fight a facial cancer that has reduced the wild population of Tasmanian devils by 80% since the 1990s. [Photo: Colossal Foundation]
Colossal Foundation Partners with the University of Tasmania to ‘Give Tasmanian Devils a Fighting Chance’
by Sandra Engelland | Jul 7, 2026
By using a vaccine and gene editing, the partners aim to fight a lethal cancer that has reduced the wild population of Tasmanian devils by 80% since the 1990s.
by Lance Murray |
Feb 13, 2024
UT Southwestern Medical Center and pharmaceutical company Pfizer have teamed up to develop new ways to deliver genetic treatments to patients.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
MORE►
by Quincy Preston and Lance Murray |
Sep 19, 2023
With only two known living female northern white rhinos left, Colossal Biosciences and BioRescue have joined forces to fend off a looming extinction of the species. At the cutting edge of science, they're harnessing genetic technologies to rewrite the rhino's fate.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
The Tasmanian tiger went extinct due to human hunting nearly 100 years ago. Now Dallas-based Colossal Biosciences aims to bring it back with the help of "marsupial biobanking." [Image: Colossal Biosciences]
Dallas-Based Colossal Is ‘De-Extincting’ the Tasmanian Tiger
by David Seeley | Aug 16, 2022
Colossal is already working to "de-extinct" the woolly mammoth via a mammoth-elephant hybrid project. Now the Tasmanian tiger—which went extinct nearly 100 years ago due to human hunting—is the second species Colossal is seeking to bring back.
"We’re thrilled to be collaborating with Andrew Pask and the University of Melbourne to restore this amazing animal to Earth," said Ben Lamm, Colossal's co-founder and CEO.
MORE►
by Lance Murray |
Jun 17, 2019
The biotech company uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, and was co-founded by UTSW researcher and faculty member Eric Olson.
MORE►
by Lance Murray |
Sep 7, 2018
Also, you'll learn about advances to treat Duchenne muscular dystrophy and migraines. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
